- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01001702
Oral Aripiprazole Open-Label Rollover Study
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241
Přehled studie
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina
- Study Site
-
Mendoza, Argentina
- Study Site
-
-
-
-
-
Split, Chorvatsko
- Study Site
-
-
-
-
-
Hyderabad, Indie
- Study Site
-
Ludhiana, Indie
- Study Site
-
Mumbai, Indie
- Study Site
-
Tamilnadu, Indie
- Study Site
-
-
-
-
-
Moscow, Ruská Federace
- Study Site
-
Rostov-on-Don, Ruská Federace
- Study Site
-
St.Petersburg, Ruská Federace
- Study Site
-
Yaroslavl, Ruská Federace
- Study Site
-
-
-
-
-
Belgrade, Srbsko
- Study Site
-
Novi Sad, Srbsko
- Study Site
-
-
-
-
-
Kharkiv, Ukrajina
- Study Site
-
Kiev, Ukrajina
- Study Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia
Exclusion Criteria:
- Patients with a co-morbid serious, uncontrolled systemic illness
- Patients with a significant risk of committing suicide
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Oral Aripiprazole
Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
|
Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
Časové okno: Up to 72 months
|
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention. Additional information about Adverse Events can be found in the Adverse Event section. |
Up to 72 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score
Časové okno: Baseline, Last Visit (Up to 72 Months)
|
The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement |
Baseline, Last Visit (Up to 72 Months)
|
Number of Participants With Clinical Significant Laboratory Tests
Časové okno: Baseline, Up to 72 Months
|
Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory. Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase > 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years [Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)]. Eosinophils ≥ 10 %. Hematocrit < 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline. Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin > 1 times the upper limit of normal [Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)]. |
Baseline, Up to 72 Months
|
Number of Participants With Clinically Significant Heart Rate
Časové okno: Baseline, Up to 72 months
|
Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing.
A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline.
A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.
|
Baseline, Up to 72 months
|
Number of Participants With Clinically Significant Blood Pressure
Časové okno: Baseline, Up to 72 months
|
Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing. Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline. A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline. |
Baseline, Up to 72 months
|
Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations
Časové okno: Baseline, Up to 72 months
|
A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged. Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline. Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline. Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline. |
Baseline, Up to 72 months
|
Number of Participants Showing Significant Weight Gain or Loss
Časové okno: Baseline, Up to 72 months
|
Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72.
A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline.
A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.
|
Baseline, Up to 72 months
|
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
Časové okno: Baseline, Up to 72 months
|
The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit.
Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity).
The number of participants experiencing suicidal ideation or suicidal behavior is reported.
|
Baseline, Up to 72 months
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Duševní poruchy
- Schizofrenní spektrum a jiné psychotické poruchy
- Schizofrenie
- Fyziologické účinky léků
- Neurotransmiterové látky
- Molekulární mechanismy farmakologického působení
- Depresiva centrálního nervového systému
- Antipsychotické látky
- Uklidňující prostředky
- Psychotropní drogy
- Serotoninové látky
- Antidepresiva
- Agonisté dopaminu
- Dopaminové látky
- Agonisté serotoninového 5-HT1 receptoru
- Agonisté serotoninových receptorů
- Antagonisté serotoninového 5-HT2 receptoru
- Antagonisté serotoninu
- Antagonisté dopaminového D2 receptoru
- Antagonisté dopaminu
- Aripiprazol
Další identifikační čísla studie
- 31-05-243
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Aripiprazole
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityDokončenoZávislost na alkoholuSpojené státy
-
Otsuka Beijing Research InstituteDokončeno
-
University of California, Los AngelesAlkermes, Inc.UkončenoAripiprazol Lauroxil pro prevenci psychotického relapsu po počáteční epizodě schizofrenie (APPRAISE)Schizofrenie | Schizofreniformní porucha | Schizoafektivní porucha, depresivní typSpojené státy
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.DokončenoSchizofrenieSpojené státy
-
Otsuka Pharmaceutical Co., Ltd.Dokončeno
-
Otsuka Pharmaceutical Development & Commercialization...DokončenoSchizofrenieKorejská republika, Spojené státy, Estonsko, Itálie, Maďarsko, Bulharsko, Chorvatsko, Francie, Polsko, Thajsko, Portoriko, Chile, Jižní Afrika, Rakousko, Belgie
-
Veterans Medical Research FoundationBristol-Myers SquibbDokončeno
-
Alkermes, Inc.DokončenoSchizofrenieSpojené státy
-
Central Hospital, Nancy, FranceDokončenoSepse | Závažné onemocnění | Septický šok | Toxicita antibiotikFrancie
-
Alkermes, Inc.DokončenoSchizofrenieSpojené státy